VIIIth myelomatosis trial

Medical Research Council (MRC) (UK)0 个研究点目标入组 0 人开始时间: 2000年10月25日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients with definite myelomatosis requiring chemotherapy in the judgement of the physician and fulfilling at least two of the three following criteria: Bone marrow aspirate and/or trephine showing the presence of a neoplastic plasma cell infiltrate and/or microplasmacytomas; A paraprotein present in the blood and/or urine; Definite lytic bone lesions
•2. Aged less than 65 years
•3. Patients with equivocal myelomatosis are excluded
•4. No previous cytotoxic chemotherapy, except prednisolone or other corticosteroids to relieve fluid-unresponsive hypercalcaemia or minimal local radiotherapy to relieve bone pain
•5. No medical contraindications to protocol treatments
•6. Patients must have a neutrophil count of at least 1.3 x 10E9/l and a platelet count of at least 75 x 10E9/l
•7. Patients must be able to tolerate a daily fluid intake of not less than 3 litres, evidence of renal insufficiency following pre-treatment re-hydration does not necessarily exclude
•8. Patients must be apyrexial and free from infection

发起方

Medical Research Council (MRC) (UK)